The slide deck was presented at the Bio Data World Congress in Basel on Dec. 04, 2019. It shares first results from the work in the HiGHmed consortium on the use case oncology.

1. Patient Journey in Oncology 2025:
Molecular Tumour Boards in Practice
Dr.-Ing. Matthieu-P. Schapranow
Bio Data World Congress, Basel, Switzerland
Dec 04, 2019

2. ■ 1998: Founded as public-private partnership in Potsdam, Germany
■ 15+ professors, 600+ B.Sc. & M.Sc. students, 170+ PhD students
■ Since 2017 Digital Engineering Faculty of Potsdam University
■ Digital Health Center: Connected Health, Digital Health & Machine Learning,
Personalized Medicine, In-Memory Computing for Digital Health
Hasso Plattner Institute
Key Facts
Patient Journey in
Oncology 2025
2
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019

3. ■ Long-lasting digital health expertise and access
to global network of subject-matter experts
■ Database: In-memory database technology
for real-time data analysis
■ Methods: Latest artificial intelligence
and machine learning algorithms optimized
for scalable high-throughput processing
■ High-throughput processing of *omics data and
big medical data modalities
Working Group In-Memory Computing for Digital Health
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
3

4. ■ 150 MEUR national initiative to support adaption of digital health
■ HiGHmed consists of international partners from, e.g. hospitals,
academia, and industry.
■ Clinical Use Cases
□ Oncology
□ Cardiology
□ Infection control
■ Education: Curriculum for experts, e.g. data scientists, data stewards
Medical Informatics Initiative
HiGHmed Consortium
Schapranow, Artificial vs.
Human Intelligence, Dec
11, 2019
Lecture Series on
Global Health
4

5. ■ Case vignette: 65-year old, male, former smoker, COPD patient
■ How does the patient journey looks like?
Patient Journey: Lung Cancer in 2025
Screening, Diagnosis, Treatment, and Prevention
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
5

6. ■ Organ-specific tumor boards
■ Therapy options according to
clinical guidelines are
discussed per patient
■ Limitations:
□ Classification of cancer by
finding site
□ Personal genetic
dispositions hardly taken
into account
□ Molecular-genetic data is
rarely used
State-of-the-art Tumor Boards
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
6
https://www.nct-heidelberg.de/en/for-patients/treatment/tumor-board.html

7. State-of-the-art MTB Meetings:
Unstructured Data
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
7

8. ■ Multi-disciplinary exchange format for precision oncology
■ Incorporates all personal genetic dispositions
■ Applying engineering methodologies to support clinical findings
Motivation: Molecular Tumor Boards enabling
Precision Oncology
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
8

9. Personas and User Roles
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
9
Patient and
treating
physician
Wet Lab
Bio-
informatician
Moderator and
MTB attendees
MTB research
expert
Documenter

10. ■ Lung function test + low-dose CT scan of the lung
■ AI system supports radiologists in detecting lung tissue changes
■ Minimal invasive CTC test reveals cells carrying relevant genetic
changes, e.g. EGFR+ and ERBB2+
■ à Biopsy from lung validated hypothesis
Patient Journey: Lung Cancer in 2025
Diagnosis
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
10
https://www.plattform-lernende-systeme.de/anwendungsszenario-2.html

11. Precision Oncology driven by Data
■ Image screening:
■ Molecular-genetic profiling:
□ Send tumor sample to laboratory for DNA extraction
□ Sequencing of tumor DNA with NGS technology < 20hrs à 500GB+ raw data
□ Process raw data, i.e. perform alignment, variant calling
□ Identifying relevant variants and annotating them requires access to global
medical knowledge, e.g. latest clinical guidelines and similar cases Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
11

12. Our Approach: AnalyzeGenomes.com
In-Memory Computing Platform for Big Medical Data
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
12
In-Memory Computing Platform
Extensions for Life Sciences
Data Exchange,
App Store
Access Control,
Data Protection
Fair Use
Statistical
Tools
Real-time
Analysis
App-spanning
User Profiles
Combined and Linked Data
Genome
Data
Cellular
Pathways
Genome
Metadata
Research
Publications
Pipeline and
Analysis Models
Drugs and
Interactions
Drug Response
Analysis
Pathway Topology
Analysis
Medical
Knowledge CockpitOncolyzer
Clinical Trial
Recruitment
Cohort
Analysis
...
Indexed
Sources

13. ■ AI-based therapy support based on, e.g.
□ Clinical guidelines
□ Historic patient cases
□ Latest international medical
knowledge and publications
■ à Fully compliant with latest clinical
guidelines surgery can be performed
Patient Journey: Lung Cancer in 2025
Treatment
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
13
https://we.analyzegenomes.com/mkc/digiGipfel2018/

14. I. Clinical Process: MTB Preparation
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
14
■ Patient is sent to MTB by treating
oncologist
■ Tissue sample is processed in wet lab
■ Bioinformatics department processes
sequenced DNA reads
■ MTB research expert annotates
mutations to identify treatment
alternatives:
□ Time-intense
□ May consume hours to days

15. ■ Variety of knowledge sources
need to be screened:
□ Variant databases,
□ Clinical trials,
□ Cancer pathways,
□ Clinical guidelines, and
□ Primary literature
World Knowledge:
Knowledge Bases for Precision Oncology
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
15

16. World Knowledge:
Annotation of Genetic Variants by MTB Research Expert
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
16
■ Understand biological function of genetic variants
■ Assess drugability of genetic changes
■ Derive treatment suggestions

17. ■ Comparison of outcome of similar patients
■ Quantitative real-time analysis of therapy efficiency
■ Assessment of alternative therapy options
■ Break-through: bringing clinical trials to participants
■ à Adjuvant therapy based on specific
combination of chemotherapy is selected
Patient Journey: Lung Cancer in 2025
Treatment
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
17
https://we.analyzegenomes.com/mkc/digiGipfel2018/

18. ■ Knowledge is scattered across hospitals
■ Variant annotation requires a collaborative
approach
□ Searching for similar patients
□ Shared knowledge bases
Community Knowledge
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
18

19. World Knowledge:
Medical Knowledge Cockpit
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
19
■ Query oriented search
interface
■ Seamless combination
with patient specifics
and annotation tools
■ Widget structure for
extensibility, e.g. for
integration of variant
databases

20. II. Clinical Process: MTB Meeting
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
20
■ Treating physician
introduces the case
■ Moderator presents case
information and treatment
suggestions to MTB
attendees
■ Documenter records final
MTB suggestions

21. ■ Short-term: patient needs to be discussed
again in future tumor board meeting
■ Long-term: evaluation of success of
experimental treatment suggestions to
collect evidence for future patients
■ Vision: personalized notifications for
patients for re-examination
III. Follow-Up
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
21

22. Stay in Contact
Dr.-Ing. Matthieu-P. Schapranow
Group Leader & Scientific Manager Digital Health Innovations
Hasso Plattner Institute
Digital Health Center
Rudolf-Breitscheid-Str. 187
14482 Potsdam, Germany
we.analyzegenomes.com
@AnalyzeGenomes
Schapranow, Bio Data
World Congress, Basel,
Dec 04, 2019
Patient Journey in
Oncology 2025
22